A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

To evaluate the safety and tolerability of multiple, ascending doses of PF-04958242 administered orally to psychiatrically stable subjects with schizophrenia receiving antipsychotic and adjunctive medication.

Key facts

Study ID

NCT01518894

Run by

Biogen

People needed

30

Starts

2011-11-01

Expected to finish

2012-03-01

Last updated by the study team

2019-11-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Psychiatrically stable subjects with schizophrenia
• Evidence of stable schizophrenia symptomatology ≥ 3 months
• Score on MCCB Letter-number span + Spatial span subtest < 40.

You may not qualify if…

• History of seizures or of a condition with risk of seizures
• History of abnormal EEG.
• Pregnant or nursing females, and women of child bearing potential

Where it is running

• Pfizer Investigational Site — Long Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.